Join Growin Stock Community!

Sab biotherapeutics, inc.SABSW.US Overview

US StockHealthcare
(No presentation for SABSW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SABSW AI Insights

SABSW Overall Performance

SABSW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SABSW Recent Performance

-

Sab biotherapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SABSW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SABSW Key Information

SABSW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SABSW Profile

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

Price of SABSW

SABSW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SABSW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
0.10
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-2647.64%
Net Margin
-18629.86%
Revenue Growth (YoY)
-92.42%
Profit Growth (YoY)
10.81%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
0.10
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-2647.64%
Net Margin
-18629.86%
Revenue Growth (YoY)
-92.42%
Profit Growth (YoY)
10.81%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-%

  • When is SABSW's latest earnings report released?

    The most recent financial report for Sab biotherapeutics, inc. (SABSW) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SABSW's short-term business performance and financial health. For the latest updates on SABSW's earnings releases, visit this page regularly.

  • How much debt does SABSW have?

    As of the end of the reporting period, Sab biotherapeutics, inc. (SABSW) had total debt of 6.19M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SABSW have?

    At the end of the period, Sab biotherapeutics, inc. (SABSW) held Total Cash and Cash Equivalents of 29.42M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SABSW's EPS continuing to grow?

    According to the past four quarterly reports, Sab biotherapeutics, inc. (SABSW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SABSW?

    Sab biotherapeutics, inc. (SABSW)'s Free Cash Flow (FCF) for the period is -13.05M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 104.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SABSW?

    The latest valuation data shows Sab biotherapeutics, inc. (SABSW) has a Price-To-Earnings (PE) ratio of 0.12 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.